Insider Shareholders with Direct Ownership of An2 Therapeutics, Inc. (ANTX)
This section provides a comprehensive overview of the insiders with direct ownership of An2 Therapeutics, Inc. (ANTX). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
AN2 Therapeutics, Inc. Insider List
| Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
|---|---|---|---|---|---|
| 0 | 214,777 | 2,184,224 $2.38 Million | 11 |
Jun 06, 2022
Reduced 1.2%
|
|
|
Eric Easom
Chief Executive Officer |
103,907 | 97,008 | 101,130 $110,231 | 19 |
Mar 15, 2024
Added 49.47%
|
| 98,199 | 0 | 98,199 $107,036 | 1 |
Mar 29, 2022
Added 50.0%
|
|
|
Joshua M Eizen
Chief Legal Officer |
90,000 | 0 | 94,833 $103,367 | 2 |
Jul 10, 2024
Added 38.75%
|
|
Paul Eckburg
Chief Medical Officer |
30,000 | 0 | 51,416 $56,043 | 1 |
Mar 15, 2024
Added 36.85%
|
|
Kevin Michael Krause
Chief Strategy Officer |
40,000 | 10,000 | 31,914 $34,786 | 5 |
Mar 15, 2024
Added 48.45%
|
|
Lucy Day
Chief Financial Officer |
27,500 | 0 | 30,627 $33,383 | 1 |
Mar 15, 2024
Added 47.31%
|
|
Sanjay Chanda
Chief Development Officer |
27,500 | 0 | 28,235 $30,776 | 1 |
Mar 15, 2024
Added 49.34%
|